Background/Aims: To assess if cardiovascular disease risk factors (CVDRF) are predictive factors for poorer evolution of Alzheimer’s disease (AD) patients in terms of cognitive decline. Methods: The Réseau de la maladie d’Alzheimer – France (REAL.FR) study is a prospective multicentre cohort which has recruited 686 community-dwelling patients presenting mild to moderate AD. The presence of CVDRF and associated treatments was recorded at baseline. The rate of cognitive decline of AD patients was assessed using the Mini Mental State Examination (MMSE) and the Alzheimer Disease Assessment Scale cognitive subscale (ADAS-Cog), after 2 years of follow-up. Results: Of the 629 patients at baseline, 268 (42.6%) had no CVDRF, 256 (40.7%) reported 1 CVDRF and 105 (16.7%) reported 2–3. At inclusion, hypertension was present in 44.1% of patients, hypercholesterolaemia in 22.6% and diabetes in 9.4%. No statistically significant differences (p values of 0.9 for MMSE and 0.8 for ADAS-Cog) in mean cognitive decline after 2 years of follow-up were found comparing different subgroups of patients with CVDRF to the non-CVDRF group. Conclusions: Although there is evidence that CVDRF contribute to the onset of AD, these results suggest that CVDRF may not be part of the underlying processes that affect progression of AD.

Keywords:
Geriatrics, Cardiovascular disease risk factors, older people, Hypertension, Diabetes, Hypercholesterolaemia, Alzheimer’s disease, epidemiology
This content is only available via PDF.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.